faculty portrait if available
Paul Sylvester
Professor
Basic Pharmaceutical Sciences
PHAR 342
318-342-1958
ULM logo

Paul W Sylvester, PhD
Professor, Pharmacy
Director of Graduate Studies and Research (Pharmacy)

Education

Ph D

1982, Physiology
Michigan State University

BS

1976, Biology
Western Michigan University

faculty feature photo

Biographical Sketch

Dr. Sylvester received his B.S. degree in biology from Western Michigan University in Kalamazoo, MI, his Ph.D. from Michigan State University in East Lansing, MI, and received postdoctoral training at Roswell Park Cancer Institute in Buffalo, NY.  Prior to his arrival at ULM, Dr. Sylvester was a faculty member for ten years in the College of Pharmacy at Washington State University in Pullman, WA.  Dr. Sylvester is an endocrinologist and his research interests have focused on endocrine-dependent diseases, particularly breast cancer.  Dr. Sylvester’s laboratory is currently examining the mechanisms mediating the antiproliferative and apoptotic effects of tocotrienols, a rare natural form of vitamin E, in breast cancer cells.  Dr. Sylvester has maintained an active research program supported by grants from the National Cancer Institute at NIH, American Cancer Society, and American Institute of Cancer Research, and First Tech International Ltd, Louisiana Cancer Foundation, among others.  Dr. Sylvester has authored over 140 peer reviewed research publications, 18 book chapters, and has presented more than 154 talks at national and international scientific conferences.  Dr. Sylvester was awarded eight teaching awards during the past 24 years.  

Research Interests

  Our laboratory has been involved in breast cancer research for many years that has focused on developing tocotrienols, a natural form of vitamin E, as a clinical treatment for breast cancer in women.  My research will provide information that will determine the potential health benefits of various natural products in the prevention and/or treatment of breast cancer in women.  We also received research grants this past year from the Louisiana Cancer Foundation.  

Recent Publications

Briski, K. P., Alenazi, F., Shakya, M., Sylvester, P. W. (2017). Hindbrain A2 Noradrenergic Neuron Adenosine 5’-Monophosphate-Activated Protein Kinase (AMPK) Activation, Upstream Kinase/Phosphorylase Protein Expression, and Receptivity to Hormone and Fuel Reporters of Short-Term Food Deprivation are Regulated by Estradiol. (pp. 1427-1437). Journal of Neuroscience.
Sylvester, P. w., Tiwari, R. V. (2016). Role of Autophagy in Mediating the Anticancer Effects of Tocotrienols. (pp. 89-104). Rijeka: Autophagy in Current Trends in Cellular Physiology and Pathology.
Alawin, O. A., Ahmed, R. R., Dronamraju, V., Algayadh, I. G., Kalloub, A. A., Sylvester, P. W. (2016). Role of Endoplasmic Retiulum Stress in Mediating the Anticancer Effects of Tocotrienols. (pp. 101-128). Hauppauge, NY.: Nova Science Publisher.
Algayadh, I. G., Sylvester, P. W. (2017). Synergistic Anticancer Effects of Combined -Tocotrienol and Pterostilbene Is Associated With a Suppression in Rac1/WAVE 2 Signaling in Highly Malignant Breast Cancer Cells. Biological and Pharmaceutical Bulletin.
Alawin, O. A. (2017). γ-Tocotrienol-Induced Disruption of Lipid Rafts in Human Breast Cancer Cells is Associated with a Reduction in Exosome Heregulin Content. Journal of Nutrition and Biochemistry.
Briski, K. P., Alenazi, F., Shakya, M., Sylvester, P. W. (2017). Hindbrain A2 Noradrenergic Neuron Adenosine 5’-Monophosphate-Activated Protein Kinase (AMPK) Activation, Upstream Kinase/Phosphorylase Protein Expression, and Receptivity to Hormone and Fuel Reporters of Short-Term Food Deprivation are Regulated by Estradiol. Journal of Neuroscience.
Algayadh, E. G., Dronamraju, V., Sylvester, P. W. (2016). gamma-Tocotrienol Inhibition of Cell Migration and Invasion Is Associated With a Suppression in WAVE 2 Signaling in Highly Malignant Breast Cancer Cells. (pp. 1974-1982). Biological and Pharmaceutical Bulletin.
Ahmed, A. R., Alawin, O. A., Sylvester, P. W. (2016). γ-Tocotrienol reversal of Epithelial-to-Mesenchymal Transition in Human Breast Cancer Cells is Associated with an Inhibition in Canonical Wnt Signaling. (pp. 460-470). Cell Proliferation.
Klionsky, D. J., Abdelmoshsen, K., Abe, A. (2016). 136. Klionsky, D.J., Abdelmoshsen, K., Abe, A., et al. (2016) Guidelines for the use and interpretation of assays for monitoring autophagy (3nd edition). (pp. 1-222). Autophagy.
Alawin, O. A., Ahmed, R. A., Ibrahim, B. A., Briski, K. P., Sylvester, P. W. (2016). Antiproliferative effects of γ-tocotrienol are associated with lipid raft disruption in HER2 positive breast cancer cells. (pp. 266-277). Journal of Nutritional Biochemistry.
Tiwari, R. V., Parajuli, P., Sylvester, P. W. (2015). Tiwari, R.V., Parajuli, P. and Sylvester, P.W. (2015) Synergistic Anticancer Effects of Combined γ-Tocotrienol and Oridonin Treatment is Associated with the Induction of Autophagy. (pp. 123-137). Molecular and Cellular Biochemistry.
Parajuli, P., Tiwari, R. V., Sylvester, P. W. (2015). Anticancer Effects of γ-Tocotrienol are Associated with a Suppression in Aerobic Glycolysis (pp. 1352-1360). Biological and Pharmaceutical Bulletin..
Parajuli, P., Tiwari, R. V. (2015). Antiproliferative Effects of γ-Tocotrienol are Associated with a Suppression in c-Myc Expression in Mammary Tumor Cells”. (pp. 421-432). Cell Proliferation.
Alqahtani, S., Simon, L., Alayoubi, A., Sylvester, P. W., Nazzal, S., Shen, Y., Xu, Z., Kaddoumi, A., Sabliov, C. M. (2015). (pp. 243-251). Journal of Colloid and Interface Science.
Sylvester, P. W. (2014). Combined γ-Tocotrienol and Met Inhibitor Treatment Suppresses Mammary Cancer Cell Proliferation, Epithelial-to-Mesenchymal Transition, and Migration. (pp. 18-30). Journal of Oil Palm, Environment & Health.
Tiwari, R., Parajuli, P., Sylvester, P. (2015). γ-Tocotrienol-Induced Autophagy Promotes Endoplasmic Reticulum Stress Mediated Apoptosis in Breast Cancer. (pp. 306-320). Biochemistry and Cell Biology.
Sylvester, P. (2014). Targeting Met mediated epithelial-mesenchymal transition in the treatment of cancer. (pp. http://www.clintransmed.com/content/3/1/30). Clinical and Translational Medicine.
Ananthula, S., Parajuli, P., Behery, F. A., El Sayed, K. A., Sylvester, P. W. (2014). δ-Tocotrienol Oxazine Derivative Antagonizes Mammary Tumor Cell Compensatory Responses to CoCl2-Induced Hypoxia. (pp. doi: 10.1155/2014/285752.). Biomed Res International.
Alqahtani, S., Alayoubi, A., Nazzal, S., Sylvesterr, P. W., Kaddoumi, A. (2014). Enhanced solubility and oral bioavailability of γ-tocotrienol using a self-emulsifying drug delivery system (SEDDS). (pp. 819-829). Lipids.
Ananthula, S., Parajuli, P., Behery, F., Alayoubi, A., El Sayed, K., Nazzal, S., Sylvester, P. (2014). Oxazine Derivatives of γ- and δ- Tocotrienol Display Enhanced Anticancer Activity In Vivo (pp. 2715-2726). Anticancer Research.
Alayoubi, A., Ayoub, N., Malaviya, A., Sylvester, P., Nazzal, S. (2014). Entrapment Into Nanoemulsions Potentiates the Anticancer Activity of Tocotrienols Against the Highly Malignant (+SA) Mouse Mammary Epithelial Cells. (pp. 4002-4005). Journal of Nanoscience and Nanotechnology.
Malaviya, A., Sylvester, P. (2014). Antiproliferative Effects of combined treatment of γ–Tocotrienol with PPARγ Agonists or Antagonists mediated through PPARγ-independent mechanisms in breast cancer cells. (pp. http://dx.doi.org/10.1155/2014/439146.). PPAR Research.
Sylvester, P., Ananthula, S., Parajuli, P., Akl, M., Malaviya, A., Tiwari, R., Ayoub, N. (2014). Potential role of tocotrienols in the treatment and prevention of breast cancer. (pp. 49-58). Biofactors.
Tiwari, R., Parajuli, P., Sylvester, P. (2014). gamma-Tocotrienol-Induced Autophagy in Malignant Mammary Cancer Cells. (pp. 33-44). Experimental Biology and Medicine.
Ayoub, N., Sylvester, P. (2013). Combined γ-Tocotrienol and Met Inhibitor Treatment Suppresses Cancer Cell Proliferation, Epithelial-to-Mesenchymal Transition, and Migration. (pp. 538-553). Cell Proliferation.
Sylvester, P., Ayoub, N. (2013). Tocotrienols Target PI3K/Akt Signaling in Anti-Breast Cancer Therapy. (pp. 1039-1047). Anti-Cancer Agents in Medicinal Chemistry.
Alqahtani, S., Alayoubi, A., Nazzal, S., Sylvester, P., Kaddoumi, A. (2013). Non-Linear Absorption Kinetics of Self-Emulsifying Drug Delivery Systems (SEDDS) Containing Tocotrienols as Lipophilic Molecules: In Vivo and In Vitro Studies. American Association of Pharmaceutics Journal.
Malaviya, A., Parajuli, P., Sylvester, P. (2014). Synergistic Antiproliferative Effects of Combined PPARγ Antagonist and γ-Tocotrienol Treatment Suppress Adipogenic Factors in Breast Cancer Cells. JPANS.
Alayoubi, A., Nazzal, M., Sylvester, P., Nazzal, S. (2013). Vitamin E” fortified parenteral lipid emulsions: Plackett-Burman screening of primary process and composition parameters. (pp. 363-373). Drug Development and Industrial Pharmacy.
Alayoubi, A., Kanthala, S., Satyanarayanajois, S., Anderson, J., Sylvester, P., Nazzal, S. (2013). Stability and in vitro antiproliferative activity of bioactive “Vitamin E” fortified parenteral lipid emulsions (pp. 23-30). Colloids and Surfaces B: Biointerfaces.
Radwan, M., Manly, S., El Sayed, K., Wali, V., Sylvester, P. W., Awate, B., Shah, G., Ross, S. (2008). Sinulodurins A and B, Antiproliferative and Anti-invasive Diterpenes from the Soft Coral Sinularia dura (pp. 1468-1471). Journal of Natural Products.
El Sayed, K., Laphookhieo, S., Yousaf, M., Prestridge, J., Shirode, A., Wali, V., Sylvester, P. W. (2008). Semisynthetic and biocatalytic anticancer optimization of tobacco (1S, 2E, 4S, 6R, 7E, 11E) – 2,7,11-cembratriene-4,6-diol (pp. 117-122). Journal of Natural Products.
Sylvester, P. W., Bachawal, S. V., Wali, V. B., Shirode, A. V. (2008). Epidermal Growth Factor Receptor Dependent Mitogenic Signaling in Normal and Malignant Mammary Epithelial Cells. (pp. 139-157). Nova Science Publishers, Inc., Hauppauge, NY: Cellular Growth Processes.
Abdel Bar, F., Zaghloul, A., Bachawal, S., Sylvester, P. W., Khanfar, M., El Sayed, K. (2008). Antiproliferative Triterpenes from Melaleuca ericifolia (pp. 1787-1790). Journal of Natural Products.
Sylvester, P. W. (2008). Antiproliferative and Apoptotic Effects of Tocotrienols on Normal and Neoplastic Mammary Epithelial Cells (pp. 119-140). AOCS Press, Champaign, IL.: Tocotrienols: Vitamin E Beyond Tocopherols.
Abdel Bar, F. A., Khanfar, M. A., H, L., Raisch, K. P., Sylvester, P. W., Zaghloul, A. M., Badria, F. A., El Sayed, K. (2009). Rational design and semisynthesis of betulinic acid analogues as potent topoisomerase inhibitors (pp. 1643-1650). Washington DC/American Chemical Society: Journal of Natural Products.
Shirode, A. V., Sylvester, P. W. (2009). Synergistic antiproliferative effect of -tocotrienol and celecoxib on mammary tumor cells is associated with a suppression in Akt and NFκB Signaling. Biomedicine and Pharmacotherapy.
Wali, V., Bachawal, S., Sylvester, P. W. (2009). Suppression in mevalonate synthesis mediates the antitumor effects of combined statin and -tocotrienol treatment. (pp. 925-934). Lipids.
Radwan, M., Manly, S., El Sayed, K., Wali, V., Sylvester, P. W., Awate, B., Shah, G., Ross, S. (2009). Sinulodurins A and B, Antiproliferative and Anti-invasive Diterpenes from the Soft Coral Sinularia dura. (pp. 1468-1471). Journal of Natural Products.
Abdel Bar, F., Khanfar, M., Elnagar, A., Liu, H., Zahloul, A., Badria, F., Sylvester, P. W., Ahmad, D., Raisch, K., El Sayed, K. (2009). Rational Design and Semisynthesis of Betulinic Acid Analogues as Potent Topoisomerase Inhibitors. (pp. 1643-1650). Journal of Natural Products.
Sylvester, P. W., Samant, G. V., Wali, V. B., Bachawal, S. V. (2009). Intracellular Mechanisms Mediating Vitamin E Suppression of Mammary Tumor Cell Proliferation. (pp. 371-388). Nova Science Publishers, Inc., Hauppauge, NY: Handbook of Cell Proliferation.
Bachawal, S., Wali, V., Sylvester, P. W. (2009). Enhanced Antiproliferative Response to Combined -Tocotrienol and Erlotinib or Gefitinib Treatment in Mammary Tumor Cells. BioMedical Central Cancer.
Wali, V., Bachawal, S., Sylvester, P. W. (2009). Endoplasmic Reticulum Stress Mediates -Tocotrienol-Induced Apoptosis in Mammary Tumor Cells (pp. 1366-1377). Apoptosis.
Wali, V. B., Bachawal, S. V., Sylvester, P. W. (2009). Combined Treatment of -Tocotrienol with Statins Induce Mammary Tumor Cell Cycle Arrest in G1 (pp. 639-650). Experimental Biology and Medicine.
Samant, G. V., Wali, V. B., Sylvester, P. W. (2009). Antiproliferative Effects of -Tocotrienol on Mammary Tumor Cells are Associated with a Suppression in Cell Cycle Progression. Cell Proliferation.
Paatwardhan, G., Zhang, Q., Yin, D., Gupta, V., Bao, J., Xie, P., Senkal, P., Ogretmen, B., Cabot, M., Shah, G., Sylvester, P. W., Jazsinski, S., Liu, Y. (2009). A New Mixed-Backbone Oligonucleotide against Glucosylceramide Synthase Sensitizes Multidrug-Resistant Tumors to Apoptosis. (pp. e6938). PLoS One.
Elnagar, A., Sylvester, P. W., Wali, V., El Sayed, K. (2010). Design and preliminary structure-activity relationship of redox-silent semisynthetic tocotrienol analogues as inhibitors for breast cancer proliferation and invasion. (pp. 755-768). New York: Bioorganic & Medicinal Chemistry-.
Abdelbar, F., El Sayed, K., Sylvester, P. W., Raisch, K., Zaghloul, A., Badria, F., Mohammad, K., Elnagar, A. (2010). Design and pharmacophore modeling of microtubule-disrupting biaryl methyl eugenol analogs as breast cancer invasion inhibitors (pp. 496–507). Bioorganic Medicinal Chemistry/Elsevier.
Abuasal, B., Sylvester, P. W., Khalil, A. (2010). Intestinal Absorption of γ-Tocotrienol is Mediated by NPC1L1: In Situ Rat Intestinal Perfusion Studies. Drug Metabolism & Disposition.
Behery, F., Elnagar, A., Wali, V., Abouasal, B., Akl, M., Khalil, A., Sylvester, P. W., El Sayed, K. (2010). Redox-Silent Tocotrienol Esters as Breast Cancer Proliferation and Migration Inhibitors (pp. 8066-8075). New York: Bioorganic & Medicinal Chemistry, Elsevier.
Sylvester, P. W., Ayoub, N. M., Akl, M. R. (2010). Role of Natural Vitamin E in Breast Cancer Prevention and Treatment. (pp. 157-168). Nova Science Publishers, Inc., Hauppauge, NY..
Ali, H., Shirode, A., Sylvester, P. W., Nazzal, S. (2010). Preparation and In Vitro Antiproliferative Effect of Tocotrienol Loaded Lipid Nanoparticles. (pp. 223-231). International Journal of Pharmaceutics.
Abdel Bar, F., Khanfar, M., Elnagar, A., Badria, F., Zaghloul, A., Ahmad, K., Sylvester, P. W., El Sayed, K. (2010). Design and Pharmacophore Modeling of Microtubule-Disrupting Biaryl Methyl Eugenol Analogs as Breast Cancer Invasion Inhibitors. Bioorganic Medicinal Chemistry (pp. 496-507). Bioorganic Medicinal Chemistry.
Bachawal, S., Wali, V., Sylvester, P. W. (2010). Combined gamma-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in mammary tumor cells. (pp. 429-438). Anticancer Research.
AbuAsal, B., Sylvester, P. W., Kaddoumi, A. (2010). Characterization of γ-Tocotrienol Intestinal Permeability and Metabolism Using in situ Rat Intestinal Perfusion Model. Journal of Lipid Research.
Elnagar, A., Wali, V., Sylvester, P. W., El Sayed, K. (2010). ) Design and Preliminary Structure-Activity Relationship of Redox-Silent Semisynthetic Tocotrienol Analogues as Inhibitors for Breast Cancer Proliferation and Invasion. (pp. 755-768). Bioorganic & Medicinal Chemistry.
Sylvester, P. W. (2011). Tocotrienol Dietary Supplementation and Health. In: Vitamin E: Nutrition, Side Effects and Supplements, (pp. 1-43). Nova Science Publishers, Inc., Hauppauge, NY..
Sylvester, P. W. (2011). Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability. In: Drug Design and Discovery: Methods and Protocols, Methods in Molecular Biology, (pp. 157-168). Humana Press, New York, NY..
Shirode, A. B., Sylvester, P. W. (2011). Mechanisms mediating the synergistic anticancer effects of combined -tocotrienol and celecoxib treatment. Journal of Bioanalysis & Biomedicine. 3:001-007. doi:10.4172/1948-593x.1000036: Journal of Bioanalysis & Biomedicine.
Alaa, A. H., Hisham, Q., Nick, O. D., Jessica, A., Sylvester, P. W., El Sayed, K., Khalil, A. (2011). Induction of expression and functional activity of P-glycoprotein efflux transporter by bioactive plant natural products (pp. 2765-72). Food Chem Toxicol.
Sylvester, P. W., Wali, V. B., Bachawal, S. V., Shirode, A. B., Ayoub, N. M., Akl, M. R. (2011). Frontiers in Bioscience (pp. 3183-3195). Frontiers in Bioscience.
Bilal, A., Shawn, T., Sylvester, P. W., Khalil, A. (2011). Development and validation of a reversed phase HPLC method for the determination of γ-tocotrienol in rat and human plasma (pp. 621-7). Biomedical Chromatography.
Elnagar, A. Y., Sylvester, P. W., El Sayed, K. A. (2011). (-)-Oleocanthal as a c-met inhibitor for the control of metastatic breast and prostate cancers. (pp. 1-7). Planta Medica.
Alayoubi, A., Nazzal, M., Sylvester, P. W., Nazzal, S. (2012). “Vitamin E” fortified parenteral lipid emulsions: Plackett-Burman screening of primary process and composition parameters. (pp. 363-373). Drug Development and Industrial Pharmacy.
Sylvester, P. W. (2012). Tocotrienol Loaded Lipid Nanoparticles in Cancer. In: Nanomedicine and Cancer, (pp. 63-83). Science Publishers/CRC Press Taylor & Francis Group.
Sylvester, P. W. (2012). Synergistic Anticancer Effects of Combined -Tocotrienol with Statin or Receptor Tyrosine Kinase Inhibitor Treatment in Mammary Tumor Cells (pp. 63-74). Genes & Nutrition.
Alayoubi, A., Kanthala, S., Satyanarayanajois, S. D., Anderson, J. F., Sylvester, P. W., Nazzal, S. (2012). Stability and in vitro antiproliferative activity of bioactive “Vitamin E” fortified parenteral lipid emulsions. (pp. 23-30). Colloids and Surfaces B: Biointerfaces.
Akl, M. R., Ayoub, N. M., Abuasal, B., Kaddoumi, A., Sylvester, P. W. (2012). Sesamin synergistically potentiates the anticancer effects of gamma-tocotrienol in mammary tumor cell lines. (pp. 347-359). Fitoterapia.
Behery, F. A., Akl, M. R., Ananthula, S., Sylvester, P. W., El Sayed, K. A. (2012). Optimization of tocotrienols as antiproliferative and antimigratory leads. (pp. 329-341). European Journal of Medicinal Chemistry.
Alayoubi, A., Satyanarayana-Jois, S., Sylvester, P. W., Nazzal, S. (2012). Multisimplex Optimization of Tocotrienol-Rich Self Emulsified Drug Delivery Systems (pp. 153-161). International Journal of Pharmaceutics.
Alayoubi, A., Satyanarayanjois, S. D., Sylvester, P. W., Nazzal, S. M. (2012). Molecular Modeling and Multisimplex Optimization of Tocotrienol-Rich Self Emulsified Drug Delivery Systems. (pp. 153-161). International Journal of Pharmaceutics.
Sylvester, P. W., Malaviya, A., Ananthula, S., Parash, P., Tiwari, R. (2012). In: Statins: Pharmacology, Clinical Implications and Adverse Effects, (pp. 125-150). Nova Science Publishers, Inc., Hauppauge, NY..
Bilal, A., Courtney, L., Breanne, P., Alaadin, A., Nazzal, S., Sylvester, P. W., Khalil, A. (2012). Enhancement of Intestinal Permeability Utilizing Solid Lipid Nanoparticles Increases γ-Tocotrienol Oral Bioavailability (pp. 461-9). Lipids.
Abuasal, B. S., Lucas, C., Peyton, B., Alayoubi, A., Nazzal, S., Sylvester, P. W., Kaddoumi, A. (2012). Enhancement of intestinal permeability utilizing solid lipid nanoparticles increases γ-tocotrienol oral bioavailability (pp. 461-469). Lipids.
Alayoubi, A., Anderson, J. F., Satyanarayanajois, S. D., Sylvester, P. W., Nazzal, S. (2012). Concurrent delivery of tocotrienols and simvastatin by lipid nanoemulsions potentiates their antitumor activity against human mammary adenocarcinoma cells. (pp. 386-392). European Journal of Pharmaceutical Sciences.
Bilal, A., Hisham, Q., Sylvester, P. W., Khalil, A. (2012). Comparison of the intestinal absorption and bioavailability of γ-tocotrienol and α-tocopherol: in-vitro, in-situ, and in-vivo studies (pp. 246-56). Biopharm Drug Dispos.
Abuasal, B. S., Qosa, H., Sylvester, P. W., Kaddoumi, A. (2012). Comparison of the intestinal absorption and bioavailability of α-tocopherol and γ-tocotrienol: in-vitro, in-situ, and in-vivo studies. (pp. 246-256). Drug Metabolism & Disposition.
El Sayed, K., Sylvester, P. W. (2013). Discovery and optimization of tocotrienol electrophilic substitution products as antiproliferative and antimigratory leads (pp. 329-341). European Journal of Medicinal Chemistry-Elsevier.
Alayoubi, A., Nazzal, M., Sylvester, P. W., Nazzal, S. (2013). “Vitamin E” Fortified Parenteral Lipid Emulsions: Plackett-Burman Screening of Primary Process and Composition Parameters (pp. 363-373). Drug Development and Industrial Pharmacy.
Sylvester, P. W., Ayoub, N. M. (2013). Tocotrienols Target PI3K/Akt Signaling in Anti-Breast Cancer Therapy. (pp. 1039-1047). Anti-Cancer Agents in Medicinal Chemistry.
Sylvester, P. W. (2013). Tocotrienols and Cancer. Biofactors.
Alayoubi, A., Kanthala, S., Satyanarayana-Jois, S., Anderson, J. F., Sylvester, P. W., Nazzal, S. (2013). Stability and in vitro antiproliferative activity of bioactive “Vitamin E” fortified parenteral lipid emulsions (pp. 23-30). Colloids and Surfaces B: Biointerfaces.
Sylvester, P. W., Ananthula, S., Parajuli, P., Akl, M. M., Malaviya, A., Tiwari, R. A., Alawin, O., Ayoub, N. M. (2013). Potential role of tocotrienols in the treatment and prevention of breast cancer. Biofactors.
Saeed, A., Alaadin, A., Nazzal, S., Sylvester, P. W., Khalil, A. (2013). Nonlinear Absorption Kinetics of Self-Emulsifying Drug Delivery Systems (SEDDS) Containing Tocotrienols as Lipophilic Molecules: In Vivo and In Vitro Studies. AAPS Journal.
Alqahtani, S., Alayoubi, A., Nazzal, S., Sylvester, P. W., Kaddoumi, A. (2013). Non-Linear Absorption Kinetics of Self-Emulsifying Drug Delivery Systems (SEDDS) Containing Tocotrienols as Lipophilic Molecules: (pp. doi: 10.1208/s12248-013-9481-7). American Association of Pharmaceutics Journal.
Akl, M. M., Ayoub, N. M., Sylvester, P. W. (2013). Mechanisms mediating the synergistic anticancer effects of combined gamma-tocotrienol and sesamin treatment. (pp. 1731-1739). Planta Medica.
Malaviya, A., Sylvester, P. W. (2013). Mechanisms mediating the effects of γ–tocotrienol used in combination with PPARγ agonists or antagonists on MCF-7 and MDA-MB-231 breast cancer cell proliferation. (pp. http://dx.doi.org/10.1155/2013/101705). International Journal of Breast Cancer.
Behery, F. A., Akl, M. R., Elnagar, A. Y., Ananthula, S., Parajuli, P., Kaddoumi, A., Sylvester, P. W., El Sayed, K. A. (2013). Mannich and Lederer-Manasse-based semisynthetic products of - and -tocotrienols as inhibitors of breast cancer cell proliferation and migration. Bioorganic and Medicinal Chemistry.
Alayoubi, A., Anderson, J. F., Satyanarayana-Jois, S., Sylvester, P. W., Nazzal, S. (2013). Concurrent delivery of tocotrienols and simvastatin by lipid nanoemulsions potentiates their antitumor activity against human mammary adenocarcenoma cells (pp. 385-392). European Journal of Pharmaceutical Sciences.
Ayoub, N. M., Akl, M. R., Sylvester, P. W. (2013). Combined -Tocotrienol and Met Inhibitor Treatment Suppresses Cancer Cell Proliferation, Epithelial-to-Mesenchymal Transition, and Migration. Cell Proliferation.
Ayoub, N. M., Akl, M. R., Sylvester, P. W. (2013). Combined -Tocotrienol and Met Inhibitor Treatment Suppresses Cancer Cell Proliferation, Epithelial-to-Mesenchymal Transition, and Migration. Cell Proliferation.
Malaviya, A., Sylvester, P. W. (2013). Mechanisms mediating the effects of γ–tocotrienol used in combination with PPARγ agonists or antagonists on MCF-7 and MDA-MB-231 breast cancer cell proliferation. International Journal of Breast Cancer.
Akl, M. R., Sylvester, P. W. (2013). Anticancer Activity of Boswellia (Frankincense) Essential Oil. In: Recent Progress in Medicinal Plants, Volume 38, “Essential Oil III and Phytopharmacology, (pp. 43-58). The Stadium Press LLC (USA), Houston, TX..
Ali, H., Shirode, A., Sylvester, P. W., Nazzal, S. (2010). Preparation and In Vitro Antiproliferative Effect of Tocotrienol Loaded Lipid Nanoparticles. Colloids and Surfaces A: Physicochemical and Engineering Aspects.

Research Grants

El Sayed, K. (Principal), Sylvester, P. W. (Co-Principal), Liu, Y. (Co-Principal), "Design of novel c-Met inhibitors inspired by olive phenolics-1R15CA167475-01" (Funded), Sponsored By NIH/NCI, External to The University of Louisiana at Monroe, $420540. (February 01 2013 - January 31 2016).
Sylvester, P. (Principal), "Breast Cancer Research" (), Sponsored By Louisiana Cancer Foundation, External to The University of Louisiana at Monroe, $20000. (October 2013 - October 2014).
Sylvester, P. W., "Optimization of Tocotrienol Extraction and Purification From Rice Bran Oil for use in the Prevention and Treatment of Breast Cancer." (Funded), Sponsored By Louisiana Campuses research Initiative (LACRI) 2012, The University of Louisiana at Monroe, $20000. (January 2013 - January 2014).
Sylvester, P. W., "Cancer Research Grant" (Funded), Sponsored By Louisiana Cancer Foundation., External to The University of Louisiana at Monroe, $10000. (January 2013 - January 2014).
Sylvester, P. (Principal), "Breast Cancer Research" (), Sponsored By Louisiana Cancer Foundation, External to The University of Louisiana at Monroe, $10000. (July 2012 - June 2013).
El Sayed, K., Nazzal, S., Sylvester, P. W., "Optimization of latrunculin-based cytotoxic agents" (Pending Funding Decision), Sponsored By NIH/NCI, External to The University of Louisiana at Monroe, $420540. (July 2010 - June 2013).
El Sayed, K., Nazzal, S., Sylvester, P. W., "Optimization of latrunculin-based cytotoxic agents" (Pending Funding Decision), Sponsored By NIH/NCI-R15/AREA, External to The University of Louisiana at Monroe, $420540. (July 2010 - June 2013).
Sylvester, P. (Principal), Nazzal, S. (Co-Principal), "Optimization and Characterization of a Novel Nanoparticle Formulation of Combined Statin and -Tocotrienol Chemotherapy for the Treatment of Breast Cancer”" (), Sponsored By Malaysian Palm Oil Council, External to The University of Louisiana at Monroe, $50000. (2010 - 2012).
El Sayed, K. (Principal), Sylvester, P. W. (Co-Principal), "Computer-assisted discovery and optimization of synergistic Met tyrosine kinase inhibitory natural products" (Pending Funding Decision), Sponsored By Department of Defense-Breast Cancer Research Program, External to The University of Louisiana at Monroe, $106500. (October 01 2010 - September 30 2011).
Meyer, S. (Principal), Briski, K. (Co-Principal), El Sayed, K. (Co-Principal), Sylvester, P. W. (Co-Principal), Liu, Y. (Co-Principal), Jackson, K. (Co-Principal), Jackson, D. (Co-Principal), Anderson, J. F., "Advancing ULM Free Radical Research through Acquision of ESR/EPR Spectrometer Advancing ULM Free Radical Research through Acquision of ESR/EPR Spectrometer" (Funded), Sponsored By LA Board of Regents-ENHANCEMENT, External to The University of Louisiana at Monroe, $173805. (June 1 2010 - June 30 2011).

Patents

Sylvester, P. (2016). Tocotrienol Derivatives and Associated Methods. US Patent No. French Patent Number EP2785722.

Sylvester, P. (2016). Tocotrienol Derivatives and Associated Methods. . US Patent No. German Patent Number 2785722.

Sylvester, P. (2016). Tocotrienol Derivatives and Associated Methods. . US Patent No. United Kingdom Patent Number EP2785722.

Sylvester, P. (2015). El Sayed, K.A. and Sylvester, P.W. Tocotrienol Esters.. US Patent No. 8969303.

Sylvester, P. (2014). El Sayed, E.A., Sylvester, P.W. and Behery, F. Tocotrienol Derivatives and Associated Methods.. US Patent No. 8816071.

Sylvester, P. (2011). Patents El Sayed, K.A., Shah, G., and Sylvester, P.W. Anticancer Tobacco Cembranoids, Submitted 12/18/08.. US Patent No. 7977384.

Sylvester, P. (2014). Sylvester, P.W. and El Sayed, K.A. Anticancer Tocotrienol Analogues and Associated Methods, Submitted 5/11/09.. US Patent No. 8266786.

Awards & Honors

August 2011 ULM Foundation Award for Excellence in Research.

October 2007 Outstanding Professor In the College of Pharmacy.

2006 Teacher of the Year.

2006 Excellence in Teaching.

2005 Teacher of the Year.

2003 Outstanding Faculty Member in the College of Pharmacy.

1998 Teacher of the Year.

1997 Teacher of the Year.

1996 Teacher of the Year.

1993 Teacher of the Year.

Courses Taught

PHAR 4013Pharmacology III, 4 course(s)

PHAR 5021ADVANCED PHARMACOLOGY, 6 course(s)

PHAR 5022Adv Pharmacology Lab, 1 course(s)

PHAR 5052SEMINAR, 25 course(s)

PHRD 4010INTRODUCTION TO PHARMACY, 4 course(s)

PHRD 4027PRINCIPLES OF DRUG ACTION II, 2 course(s)

PHRD 4035PATHOPHYSIOLOGY II, 7 course(s)

PHRD 4058NEUROLOGY & PSYCHIATRY MODULE, 6 course(s)

PHRD 4074ENDOCRINE MODULE, 5 course(s)

PHRD 5027BONE AND JOINT MODULE, 4 course(s)

PHRD 5061WOMEN'S HEALTH AND PHARMACIST, 3 course(s)

PHRD 5064PROBLEMS, 2 course(s)